Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

The Top 5 Biosimilar Articles for the Week of September 16

September 20th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of September 16, 2024.

Trastuzumab Biosimilar and Pertuzumab Effective, Safe in Neoadjuvant Breast Cancer Therapy

September 19th 2024

By Cameron Santoro

Article

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability.

AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1

September 18th 2024

By Skylar Jeremias

Article

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).

FDA Approves Pavblu for Retinal Conditions

September 17th 2024

By Skylar Jeremias

Article

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American patients with retinal diseases.

Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys

September 16th 2024

By Skylar Jeremias

Article

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.

STADA Credits Biosimilar Expansion for Profitable First Half of 2024

September 15th 2024

By Skylar Jeremias

Article

German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 billion in sales, driven in part by biosimilar successes and new product launches.

Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA

September 14th 2024

By Deana Ferreri, PhD

Article

A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.

The Top 5 Biosimilar Articles for the Week of September 9

September 13th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of September 9, 2024.

Comparable Disease Activity, Drug Persistence in Patients With JIA Who Switch to Biosimilars

September 12th 2024

By Skylar Jeremias

Article

Switching children with juvenile idiopathic arthritis (JIA) from anti–tumor necrosis factor originators to biosimilars showed similar disease activity and drug persistence, with good tolerability, supporting the safety and effectiveness of non-medical switching.

The Future of Biosimilar Gene Therapies: Key Issues and Potential

September 11th 2024

By Skylar Jeremias

Article

While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.